The approach of using pharmacologic inhibitors to target CaMKII activity has been used extensively in basic research with less progress in translational medicine, which is somewhat surprising given the widespread use of protein kinase inhibitors in cancer therapeutics for targeting tumor proliferation and cell survival (Bhullar et al., 2018). This evidence concerns the gene CAMK2G and cancer.